Khondrion announces that the first patients have been successfully dosed in its KHENEREXT Phase IIb open-label extension study
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announces that the first patients have been successfully dosed.